Abstract: Provided herein is a pharmaceutical combination comprising (a) a poly-(ADP-ribose)-polymerase (PARP) inhibitor and (b) a second agent comprising (i) an inhibitor of glycogen synthase kinase 3 (GSK-3) or (ii) an inhibitor of disrupter of telomeric silencing 1-like (DOT1L). Also provided is a method of treating a subject suffering from acute myeloid leukaemia, comprising administering to the subject a therapeutically effective amount of the pharmaceutical combination.
Type:
Grant
Filed:
November 4, 2016
Date of Patent:
October 13, 2020
Assignee:
King's College Hospital NHS Foundation Trust
Abstract: Particular aspects of the invention are methods for assaying metabolite levels in samples from a patient during pregnancy using nuclear magnetic resonance and direct flow injection mass spectrometry. In various methods, the assayed metabolites may be acylcarnitine or one or more of C3-OH (hydroxypropionylcarnitine), C5-OH (C3DC), C10, C5:1-DC (glutaconylcarnitine), C14:1-OH (hydroxytetradecenoylcarnitine) and C14:2-OH. One or more methods also may include measuring nuchal translucency of the fetus. Other methods relate to predicting fetal congenital heart defects in a fetus.
Type:
Application
Filed:
November 25, 2014
Publication date:
June 8, 2017
Applicants:
BIOSCREENING AND DIAGNOSTICS LLC, KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST
Abstract: The invention relates to materials and methods for diagnosing liver tumor types, and assessing patient prognosis. Specifically, but not exclusively, the invention concerns the determination of marker protein which enable primary liver tumors to be identified and classified according to the latest WHO classification. Particularly, the invention provides potential markers proteins which allow non-neoplastic and neoplastic hepatocytes and biliary epithelial cells to be distinguished. This allows grading of tumor differentiation to be refined and differential diagnosis of primary liver tumors and pathogenesis of sub-types of cholangiocarcinoma.
Type:
Application
Filed:
November 13, 2014
Publication date:
November 3, 2016
Applicants:
Electrophoretics Limited, King's College Hospital NHS Foundation Trust
Inventors:
Malcolm Andrew Ward, Ian Hugo Pike, David James Britton, Vikram Mitra, Nigel David Heaton, Yoh Zen, Alberto Quaglia
Abstract: The present invention concerns materials and methods relating to pancreatic cancer and personalized medicine as applied to pancreatic cancer. Particularly, the invention relates to materials and methods for the determination of significantly modulated protein phosphorylation and/or expression as well as the activity of signalling pathways collectively providing a tumour profile that can guide selection of the most appropriate treatment regime based on the likelihood of tumour recurrence or the identity of activated drug targets in pancreatic cancer.
Type:
Application
Filed:
August 13, 2014
Publication date:
July 7, 2016
Applicants:
Electrophoretics Limited, King's College Hospital NHS Foundation Trust
Inventors:
Yoh Zen, Nigel Heaton, Alberto Quaglia, David Britton, Malcolm Ward, Ian Pike, Vikram Mitra
Abstract: This invention relates to a therapeutic molecule capable of suppressing an immune response against an organ or tissue transplantation in a patient. In particular, the invention relates to a conjugate comprising a first portion connected to a second portion, wherein the first portion binds to an MHC Class I molecule and the second portion has HLA-G activity. This conjugate may be used as a medicament to modulate immune responses and induce immunological tolerance specific to allogenic MHC complexes.
Type:
Application
Filed:
November 11, 2010
Publication date:
March 28, 2013
Applicant:
King's College Hospital NHS Foundation Trust
Abstract: A phantom for determining the alignment of two or more imaging apparatuses. The phantom comprises a vessel, wherein a cavity is defined by the inner surfaces of the vessel. The cavity is for holding a fluid therein. Two or more rods extend through the cavity, the rods being non-parallel with one another.
Type:
Application
Filed:
June 23, 2008
Publication date:
September 22, 2011
Applicant:
KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST